- Home
- UZX vs LABT Comparison
UZX vs LABT Comparison
Compare UZX & LABT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UZX | LABT |
|---|---|---|
| Founded | N/A | N/A |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4M | 4.6M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | UZX | LABT |
|---|---|---|
| Price | $0.26 | $2.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 203.9K | ★ 269.5K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.19 | $2.10 |
| 52 Week High | $0.46 | $4.72 |
Technical Indicators
Market Signals| Indicator | UZX | LABT |
|---|---|---|
| Relative Strength Index (RSI) | 23.75 | 31.54 |
| Support Level | $0.19 | $2.10 |
| Resistance Level | $0.41 | N/A |
| Average True Range (ATR) | 0.05 | 0.61 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 28.08 | 19.85 |
Price Performance
Historical ComparisonAbout LABT Lakewood-Amedex Biotherapeutics Inc. Common Stock
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.